Sysora Health

East of England

Founded 2024

Targeted antibacterial gel for gum disease

Sysora Health develops a targeted antibacterial gel for periodontitis, a severe form of gum disease.

Its approach aims to eliminate Porphyromonas gingivalis, a bacterium implicated in gum inflammation, while preserving beneficial microorganisms in the oral microbiome. The company is investigating selective bacterial targeting as an alternative to broad-spectrum antimicrobial treatment.

Established in 2024, Sysora participated in Accelerate@Babraham and is based at Babraham Research Campus.

Biotech Microbiology Infectious Disease

Microbiome

Is this your company?

Claim this page to receive a verified badge and keep your profile up to date.

Claim page

Company Notes

Member of

Babraham Research Campus

Similar Companies